^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SCRI-huCAR19v1

    i
    Other names: SCRI-huCAR19v1, second generation 4 1BBζ CD19-Her2tG
    Associations

    News

    Trials
    Company:
    Seattle Children's Hospital
    Drug class:
    CD19-targeted CAR-T immunotherapy, HER2-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    5ms
    CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Seattle Children's Hospital | Phase classification: P1/2 --> P1
    Phase classification • CAR T-Cell Therapy
    |
    SCRI-huCAR19v1 • SCRI-huCAR19v2
    over2years
    PLAT-02: A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia (clinicaltrials.gov)
    P1/2, N=167, Active, not recruiting, Seattle Children's Hospital | Trial completion date: Sep 2035 --> Jul 2036 | Trial primary completion date: Sep 2020 --> Aug 2021
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    Breyanzi (lisocabtagene maraleucel) • SCRI-huCAR19v1
    almost4years
    CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, Seattle Children's Hospital | Suspended --> Active, not recruiting | N=112 --> 16
    Clinical • Enrollment closed • Enrollment change • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    SCRI-huCAR19v1 • SCRI-huCAR19v2
    almost4years
    CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov)
    P1/2, N=112, Suspended, Seattle Children's Hospital | Recruiting --> Suspended
    Clinical • Trial suspension • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    SCRI-huCAR19v1 • SCRI-huCAR19v2
    4years
    CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Seattle Children's Hospital | Active, not recruiting --> Recruiting
    Clinical • Enrollment open • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    SCRI-huCAR19v1 • SCRI-huCAR19v2